# Staccato Loxapine in Migraine (Out Patient)

> **NCT00825500** · PHASE2 · COMPLETED · sponsor: **Alexza Pharmaceuticals, Inc.** · enrollment: 366 (actual)

## Conditions studied

- Migraine Headache

## Interventions

- **DRUG:** Inhaled Placebo
- **DRUG:** Inhaled Loxapine 1.25 mg
- **DRUG:** Inhaled Loxapine 2.5 mg

## Key facts

- **NCT ID:** NCT00825500
- **Lead sponsor:** Alexza Pharmaceuticals, Inc.
- **Sponsor class:** UNKNOWN
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2009-08
- **Final completion:** 2009-08
- **Target enrollment:** 366 (ACTUAL)
- **Last updated:** 2017-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00825500

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00825500, "Staccato Loxapine in Migraine (Out Patient)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00825500. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*